がんコンパニオン診断の世界市場：市場規模・シェア・動向分析 (製品・サービス別、技術別、疾患の種類別、最終用途別、地域別)、セグメント別予測 (2025年～2030年)

がんコンパニオン診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のがんコンパニオン診断の市場規模は2030年までに83億8,000万米ドルに達し、2025年から2030年までのCAGRは9.02％で拡大すると予測されています。

コンパニオン診断薬によって重要なゲノム情報へのアクセスが拡大することで、情報に基づいた意思決定が可能になり、患者のための標的治療アプローチの設計が可能になるため、包括的なゲノム検査とがんコンパニオン診断薬の需要が増加しています。

グリベック（イマチニブ）やハーセプチン（トラスツズマブ）など、処方前にコンパニオン診断（CDx）検査を必要とする薬剤の上市は、がんコンパニオン診断の収益を増加させています。この成長は、臨床試験中の相当数のCDx関連がん治療薬のために、将来も続くと予想されます。CDxは、治療のための独占的または包括的な検査としての機能以外に、臨床試験における参加者選択の際にも重要な役割を果たしています。患者がバイオマーカーの標的を有していれば、新薬候補がより高い奏効率を示す可能性が高まるからです。

CDxの使用に伴う経済的インセンティブは、医薬品開発者に医薬品と診断テストを組み合わせることを促しています。しかし、診断薬メーカーは、一方では支払者／医療提供者から、他方では医薬品メーカーからの相反する要求に直面しています。また、規制機関は診断薬と医薬品の開発スケジュールを一致させるために厳しい政策をとっています。そのため、診断薬メーカーは、単一の診断薬と特定の薬剤のマッチングに焦点を当てるのではなく、CDx開発の範囲を広げることが期待されています。

がんコンパニオン診断市場レポートハイライト

• 製品部門は、個別化医療の進展とがんの有病率の増加に牽引され、2024年には66.14%のシェアで市場を独占し、サービス部門は予測期間中に最も速いCAGRを記録すると予想されます。
• ポリメラーゼ連鎖反応（PCR）セグメントは2024年に28.03％のシェアで市場を独占し、次世代シーケンシング（NGS）セグメントは予測期間中に最速のCAGRを記録すると予想されます。
• 2024年には非小細胞肺がんセグメントが30.32%のシェアで市場を席巻し、予測期間中は乳がんセグメントが9.65%の最速CAGRを記録する見込みです。
• 2024年には、北米が40.17%以上で神経人工器官市場全体を支配しました。これは、神経インプラント製造業者の大きな存在感、研究開発投資の高さ、政府機関と民間機関の両方から資金が得られることによる。例えば、国防高等研究計画局（DARPA）や国立神経疾患・脳卒中研究所（NIH）は、連邦機関と協力して、神経インプラントのさらなる開発のための研究開発イニシアチブを支援する資金を提供しています。
• アジア太平洋は、安全で効果的な医療処置を推進する多国籍医療企業の参入や、消費者の意識レベルの上昇により、最も急成長している分野であると予想されています。
• 戦略的提携やM&Aは、予測期間中、業界の競争レベルを高く維持すると予想されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 がんコンパニオン診断市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
  • 市場機会
  • 市場の課題
• がんコンパニオン診断市場：分析ツール
• ビジネス環境分析
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 がんコンパニオン診断市場：製品・サービス別の推定・動向分析

• 市場シェア：製品・サービス別（2024年・2030年）
• セグメントダッシュボード
• がんコンパニオン診断市場：製品・サービス別の展望
• 市場規模の予測と動向分析（2018年～2030年）
• 製品
  • 機器
  • 消耗品
  • ソフトウェア
• サービス

第5章 がんコンパニオン診断市場：技術別の推定・動向分析

• 市場シェア：技術別（2024年・2030年）
• セグメントダッシュボード
• がんコンパニオン診断市場：技術別の展望
• 市場規模の予測と動向分析（2018年～2030年）
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンシング（NGS）
• 免疫組織化学（IHC）
• in situハイブリダイゼーション（ISH）/蛍光in situハイブリダイゼーション（FISH）
• その他の技術

第6章 がんコンパニオン診断市場：疾患の種類別の推定・動向分析

• 市場シェア：疾患の種類別（2024年・2030年）
• セグメントダッシュボード
• がんコンパニオン診断市場：疾患の種類別の展望
• 市場規模の予測と動向分析（2018年～2030年）
• 乳がん
• 非小細胞肺がん
• 大腸がん
• 白血病
• 黒色腫
• 前立腺がん
• その他

第7章 がんコンパニオン診断市場：最終用途別の推定・動向分析

• 市場シェア：最終用途別（2024年・2030年）
• セグメントダッシュボード
• がんコンパニオン診断市場：最終用途別の展望
• 市場規模の予測と動向分析（2018年～2030年）
• 病院
• 病理学/診断検査室
• 学術医療センター

第8章 がんコンパニオン診断市場：地域別の推定・動向分析

• 市場シェア分析：地域別（2024年・2030年）
• 地域別ダッシュボード
• 世界市場のスナップショット：地域別
• 市場規模の予測と動向分析（2018年～2030年）
• 北米
  • 北米：SWOT分析
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州：SWOT分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋：SWOT分析
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ：SWOT分析
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ：SWOT分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 最近の動向と影響分析：主要企業別
• 企業分類
• 企業ヒートマップ分析
• 企業プロファイル
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • F. Hoffmann-La Roche Ltd
  • BIOMERIEUX
  • Abbott
  • Leica Biosystems Nussloch GmbH
  • Guardant Health
  • EntroGen, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
• Table 3 North America oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 4 North America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 5 North America oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 6 North America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 7 U.S. oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 8 U.S. oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 9 U.S. oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 10 U.S. oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 11 Canada oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 12 Canada oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 13 Canada oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 14 Canada oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 15 Mexico oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 16 Mexico oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 17 Mexico oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 18 Mexico oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 19 Europe oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
• Table 20 Europe oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 21 Europe oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 22 Europe oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 23 Europe oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 24 Germany oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 25 Germany oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 26 Germany oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 27 Germany oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 28 UK oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 29 UK oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 30 UK oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 31 UK oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 32 France oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 33 France oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 34 France oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 35 France oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 36 Italy oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 37 Italy oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 38 Italy oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 39 Italy oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 40 Spain oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 41 Spain oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 42 Spain oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 43 Spain oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 44 Denmark oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 45 Denmark oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 46 Denmark oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 47 Denmark oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 48 Sweden oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 49 Sweden oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 50 Sweden oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 51 Sweden oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 52 Norway oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 53 Norway oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 54 Norway oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 55 Norway oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 61 China oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 62 China oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 63 China oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 64 China oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 65 Japan oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 66 Japan oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 67 Japan oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 68 Japan oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 69 India oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 70 India oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 71 India oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 72 India oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 73 South Korea oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 74 South Korea oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 75 South Korea oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 76 South Korea oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 77 Australia oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 78 Australia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 79 Australia oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 80 Australia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 81 Thailand oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 82 Thailand oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 83 Thailand oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 84 Thailand oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 85 Latin America oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 86 Latin America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 87 Latin America oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 88 Latin America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 89 Brazil oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 90 Brazil oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 91 Brazil oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 92 Brazil oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 93 Argentina oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 94 Argentina oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 95 Argentina oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 96 Argentina oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 97 MEA oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
• Table 98 MEA oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 99 MEA oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 100 MEA oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 101 MEA oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 102 South Africa oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 103 South Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 104 South Africa oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 105 South Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 106 Saudi Arabia oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 110 UAE oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 111 UAE oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 112 UAE oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 113 UAE oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
• Table 114 Kuwait oncology companion diagnostic market, by product and services, 2018 - 2030 (USD Million)
• Table 115 Kuwait oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
• Table 116 Kuwait oncology companion diagnostic market, by disease, 2018 - 2030 (USD Million)
• Table 117 Kuwait oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Oncology companion diagnostic market segmentation
• Fig. 2 Data analysis models
• Fig. 3 Market formulation and validation
• Fig. 4 Data validating & publishing
• Fig. 5 Market research process
• Fig. 6 Information procurement
• Fig. 7 Primary research
• Fig. 8 Value-chain-based sizing & forecasting
• Fig. 9 QFD modelling for market share assessment
• Fig. 10 Market formulation & validation
• Fig. 11 Commodity flow analysis
• Fig. 12 Market outlook
• Fig. 13 Segment snapshot-1
• Fig. 14 Segment snapshot-2
• Fig. 15 Competitive landscape snapshot
• Fig. 16 Market trends & outlook
• Fig. 17 Porter's five force analysis
• Fig. 18 PESTEL analysis
• Fig. 19 Oncology companion diagnostic market: Product & Services outlook key takeaways
• Fig. 20 Oncology companion diagnostic market: Product & Services movement analysis
• Fig. 21 Passive immunization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Preventive vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Oncology companion diagnostic market: Technology outlook key takeaways
• Fig. 24 Oncology companion diagnostic market: Technology movement analysis
• Fig. 25 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Next-generation Sequencing (NGS) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 mRNA-based vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Other Technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Oncology companion diagnostic market: Disease Type outlook key takeaways
• Fig. 30 Oncology companion diagnostic market: Disease Type movement analysis
• Fig. 31 Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Non-small Cell Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Leukemia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Melanoma market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Others estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Oncology companion diagnostic market: End Use outlook key takeaways
• Fig. 39 Oncology companion diagnostic market: End Use movement analysis
• Fig. 40 Hospital & retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Government suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Academic Medical Center market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Regional marketplace outlook, 2024 & 2030 (USD million)
• Fig. 44 Regional marketplace: Key takeaways
• Fig. 45 North America Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Key country dynamics
• Fig. 47 U.S. Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 Canada Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Mexico Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Europe Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Key country dynamics
• Fig. 54 UK Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Key country dynamics
• Fig. 56 Germany Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 France Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Key country dynamics
• Fig. 60 Spain Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Key country dynamics
• Fig. 62 Italy Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 Denmark Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Key country dynamics
• Fig. 66 Sweden Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Norway Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Asia Pacific Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Japan Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 China Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Key country dynamics
• Fig. 75 India Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Key country dynamics
• Fig. 77 Australia Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 South Korea Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 Thailand Oncology companion diagnostic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 Market participant categorization
• Fig. 84 Oncology companion diagnostic market position analysis, 2024
• Fig. 85 Strategic framework

Oncology Companion Diagnostic Market Growth & Trends:

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 9.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights:

• The products segment dominated the market with a share of 66.14% in 2024, driven by advancements in personalized medicine and the increasing prevalence of cancer and the services segment is expected to register the fastest CAGR during the forecast period
• The Polymerase Chain Reaction (PCR) segment dominated the market with a share of 28.03% in 2024 and the next-generation Sequencing (NGS) segment is expected to register the fastest CAGR during the forecast period
• The non-small cell lung cancer segment dominated the market, with a share of 30.32% in 2024 and the breast cancer segment is expected to register the fastest CAGR of 9.65% during the forecast period
• In 2024, North America dominated the overall neuroprosthetics market at over 40.17% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.
• Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.
• Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Oncology Companion Diagnostic Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Oncology Companion Diagnostic Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Oncology Companion Diagnostic Market: Product & Services Estimates & Trend Analysis

• 4.1. Product and Services Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Oncology Companion Diagnostic Market by Product & Services Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Product
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Instrument
    • 4.5.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Consumables
    • 4.5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Software
    • 4.5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Oncology Companion Diagnostic Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Polymerase Chain Reaction (PCR)
  • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Next-generation Sequencing (NGS)
  • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Immunohistochemistry (IHC)
  • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
  • 5.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Other Technologies
  • 5.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis

• 6.1. Disease Type Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Oncology Companion Diagnostic Market by Disease Type Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Breast Cancer
  • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Non-small Cell Lung Cancer
  • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Colorectal Cancer
  • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Leukemia
  • 6.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Melanoma
  • 6.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Prostate Cancer
  • 6.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Oncology Companion Diagnostic Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Oncology Companion Diagnostic Market by Disease Type Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Hospital
  • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Pathology/Diagnostic Laboratory
  • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Academic Medical Center
  • 7.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. North America: SWOT Analysis
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
• 8.6. Europe
  • 8.6.1. Europe: SWOT Analysis
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific: SWOT Analysis
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America: SWOT Analysis
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
• 8.9. MEA
  • 8.9.1. MEA: SWOT Analysis
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Agilent Technologies, Inc.
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments/ Strategic Initiatives
  • 9.4.2. Illumina, Inc.
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments/ Strategic Initiatives
  • 9.4.3. QIAGEN
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments/ Strategic Initiatives
  • 9.4.4. Thermo Fisher Scientific Inc.
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments/ Strategic Initiatives
  • 9.4.5. Foundation Medicine, Inc.
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments/ Strategic Initiatives
  • 9.4.6. Myriad Genetics, Inc.
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments/ Strategic Initiatives
  • 9.4.7. F. Hoffmann-La Roche Ltd
    • 9.4.7.1. Financial Performance
    • 9.4.7.2. Product Benchmarking
    • 9.4.7.3. Recent Developments/ Strategic Initiatives
  • 9.4.8. BIOMERIEUX
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments/ Strategic Initiatives
  • 9.4.9. Abbott
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments/ Strategic Initiatives
  • 9.4.10. Leica Biosystems Nussloch GmbH
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments/ Strategic Initiatives
  • 9.4.11. Guardant Health
    • 9.4.11.1. Participant's Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Recent Developments/ Strategic Initiatives
  • 9.4.12. EntroGen, Inc.
    • 9.4.12.1. Participant's Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Recent Developments/ Strategic Initiatives